Back to Search Start Over

Association of BRAF V600E mutation with survival in patients with metastatic mismatch repair-deficient colorectal cancer

Authors :
Elaine Tan
Junmin Whiting
Hao Xie
Iman Imanirad
Estrella M. Carballido
Seth Felder
Jessica M. Frakes
Qianxing Mo
Christine Marie Walko
Jennifer Permuth
Richard D. Kim
Daniel A. Anaya
Jason B. Fleming
Ibrahim Halil Halil Sahin
Source :
Journal of Clinical Oncology. 40:174-174
Publication Year :
2022
Publisher :
American Society of Clinical Oncology (ASCO), 2022.

Abstract

174 Background: Colorectal cancer (CRC), while one of the most common cancer diagnoses, can behave heterogeneously based on molecular characteristics. A subset of patients (pts) with CRC are characterized with mismatch repair deficiency (MMR-d), these pts exhibit encouraging responses to immunotherapy. The predictive nature of various factors, such as BRAF status, age, and MMR-D protein loss type, have been investigated in pts with MMR-d CRC. However, the prognostic role of these factors has not been well established. The purpose of this study was to identify characteristics that influence survival in MMR-d mCRC. Methods: This study evaluated pts with MMR-d mCRC in the Flatiron database. Overall survival (OS) was determined from date of diagnosis of stage IV disease to date of death and stratified based on age greater than or less than 50 years, BRAF mutation status, RAS mutation status, and type of MMR gene loss. For statistical analysis, the Chi-Square test was implemented to determine the prognostic significance of clinical and molecular features. Univariate and multivariate analyses were determined through the Cox regression model. Results: There were 1,101 pts in the study. The majority of pts were older than 50 (79.7%), Caucasian (75%), and had ECOG 0-1 (83.4%). Among the 803 pts with known BRAF status, 44.3% (n=356) had BRAF V600E mutation and 55.7% (n=447) were BRAF wildtype. Pts with BRAF V600E mutation had OS of 18.9 months vs. 33.2 months for pts with wild type BRAF (HR 1.52, 95% CI: 1.25-1.86, p

Details

ISSN :
15277755 and 0732183X
Volume :
40
Database :
OpenAIRE
Journal :
Journal of Clinical Oncology
Accession number :
edsair.doi...........2763aea5e052865fba6990d10a160540
Full Text :
https://doi.org/10.1200/jco.2022.40.4_suppl.174